AQA-0325 is under clinical development by Aquavit Pharmaceuticals and currently in Phase I for Unspecified Neurologic Disorders.
2don MSN
Researchers have applied AI to every step of the drug development process. But this might not be enough to design safe and effective drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback